Can this drug help shrink breast tumors in women with a higher BMI?
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if a medication (GLP1/GIP-receptor agonist) can boost the immune system to fight breast cancer before surgery. It is for postmenopausal women with early-stage, estrogen-receptor-positive, HER2-negative breast cancer who have a BMI of 27 or higher (with weight-related health issues) or a BMI of 30 or higher.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are postmenopausal (no longer having periods).
- You have early-stage breast cancer that is estrogen-receptor-positive and HER2-negative, confirmed by biopsy, and the tumor is at least 1 centimeter in size.
- Your BMI is 30 or higher, or your BMI is 27 or higher with a condition like high blood pressure, high cholesterol, sleep apnea, or heart disease.
- You have not been diagnosed with diabetes (type 1 or 2) and do not have high blood sugar levels.
- You can understand Dutch, French, or English.
- You have not used any weight-loss medications or GLP1 drugs in the last 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
This trial tests if tirzepatide, a drug that helps with weight loss, can improve outcomes for women with obesity and certain early-stage endometrial conditions before a planned hysterectomy.
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This study tests whether a diabetes medication called tirzepatide, combined with a hormone-releasing device, can help shrink or stop early-stage endometrial cancer (cancer of the uterine lining) in patients who are overweight and either cannot have surgery right away or prefer to delay it. The goal is to see if this approach can be an alternative to immediate surgery.
Hear when a new Hormone-receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.